Data From Investigational Study Demonstrates T2Candida® Panel Provides Accurate and Fast Diagnosis of Candida, a Leading Cause of Sepsis, With Only 2mL of Blood From Pediatric Patients
Download the presentation of results from an investigational study presented at the 115th General Meeting of the American Society for Microbiology (asm2015) in New Orleans.
Please note: The T2Candida Panel was cleared for marketing by the U.S. Food and Drug Administration (FDA) in September 2014 for the detection of sepsis causing Candida. T2Candida Panel performance was established in adult subjects. T2Candida Panel performance in neonates, infants, and pediatric patients has not been established.
